MX2023005203A - Nanoparticulas lipidicas para administrar vacunas de arnm. - Google Patents
Nanoparticulas lipidicas para administrar vacunas de arnm.Info
- Publication number
- MX2023005203A MX2023005203A MX2023005203A MX2023005203A MX2023005203A MX 2023005203 A MX2023005203 A MX 2023005203A MX 2023005203 A MX2023005203 A MX 2023005203A MX 2023005203 A MX2023005203 A MX 2023005203A MX 2023005203 A MX2023005203 A MX 2023005203A
- Authority
- MX
- Mexico
- Prior art keywords
- lipid nanoparticles
- mrna vaccines
- delivering mrna
- delivering
- mrna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110965P | 2020-11-06 | 2020-11-06 | |
| US202163212523P | 2021-06-18 | 2021-06-18 | |
| EP21315198 | 2021-10-13 | ||
| PCT/US2021/058250 WO2022099003A1 (en) | 2020-11-06 | 2021-11-05 | Lipid nanoparticles for delivering mrna vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005203A true MX2023005203A (es) | 2023-07-13 |
Family
ID=86184333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005203A MX2023005203A (es) | 2020-11-06 | 2021-11-05 | Nanoparticulas lipidicas para administrar vacunas de arnm. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4240335A1 (enExample) |
| JP (2) | JP7817257B2 (enExample) |
| KR (1) | KR20230104223A (enExample) |
| CN (1) | CN116406299A (enExample) |
| AU (1) | AU2021374976A1 (enExample) |
| CA (1) | CA3194325A1 (enExample) |
| CO (1) | CO2023005218A2 (enExample) |
| IL (1) | IL302631A (enExample) |
| MX (1) | MX2023005203A (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| AU2022294274A1 (en) * | 2021-06-18 | 2024-02-01 | Sanofi Pasteur Inc. | Multivalent influenza vaccines |
| US20260176618A1 (en) * | 2022-11-03 | 2026-06-25 | Modernatx, Inc. | Chemical stability of mrna |
| CN118021957A (zh) * | 2022-11-11 | 2024-05-14 | 深圳先进技术研究院 | 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用 |
| CN118021956A (zh) * | 2022-11-11 | 2024-05-14 | 深圳先进技术研究院 | 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用 |
| WO2025054383A1 (en) * | 2023-09-06 | 2025-03-13 | Modernatx, Inc. | Chemical stability of mrna |
| CN122422511A (zh) * | 2023-10-31 | 2026-07-17 | 仁景(苏州)生物科技有限公司 | 一种多价流感mRNA疫苗 |
| CN120053395A (zh) * | 2023-11-30 | 2025-05-30 | 苏州维益生物科技有限公司 | 含二硫键的核酸-脂质颗粒、药物、用途、及制备方法 |
| CN118725043B (zh) * | 2024-06-27 | 2025-12-05 | 中国人民解放军陆军军医大学 | 用于递送核酸的多肽-脂质组合物及其应用和mRNA疫苗 |
| CN121265551A (zh) * | 2024-07-02 | 2026-01-06 | 苏州星核迪赛生物技术有限公司 | 一种靶向肝实质细胞的核酸递送载体及其应用 |
| WO2026095067A1 (ja) * | 2024-11-01 | 2026-05-07 | Ａｇｃ株式会社 | 核酸送達用脂質ナノ粒子 |
| CN119746089B (zh) * | 2025-03-07 | 2025-06-13 | 细胞生态海河实验室 | 脂质纳米颗粒冷冻保护剂 |
| CN121466311A (zh) * | 2026-01-09 | 2026-02-06 | 羿美诚健(上海)生物医药有限公司 | 一种脂质组合物及其在核酸递送中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3122878T3 (pl) * | 2014-03-24 | 2019-06-28 | Translate Bio, Inc. | TERAPIA mRNA DO LECZENIA CHORÓB OCZU |
| RS64331B1 (sr) * | 2015-06-19 | 2023-08-31 | Massachusetts Inst Technology | Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta |
| TW202309002A (zh) * | 2021-04-15 | 2023-03-01 | 美商轉譯生技公司 | 基於「古德」緩衝液的陽離子脂質 |
-
2021
- 2021-11-05 CN CN202180073816.5A patent/CN116406299A/zh active Pending
- 2021-11-05 KR KR1020237018750A patent/KR20230104223A/ko active Pending
- 2021-11-05 JP JP2023526888A patent/JP7817257B2/ja active Active
- 2021-11-05 IL IL302631A patent/IL302631A/en unknown
- 2021-11-05 EP EP21815832.7A patent/EP4240335A1/en active Pending
- 2021-11-05 AU AU2021374976A patent/AU2021374976A1/en active Pending
- 2021-11-05 MX MX2023005203A patent/MX2023005203A/es unknown
- 2021-11-05 CA CA3194325A patent/CA3194325A1/en active Pending
-
2023
- 2023-04-25 CO CONC2023/0005218A patent/CO2023005218A2/es unknown
-
2026
- 2026-02-05 JP JP2026017400A patent/JP2026089059A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL302631A (en) | 2023-07-01 |
| JP7817257B2 (ja) | 2026-02-18 |
| JP2026089059A (ja) | 2026-05-29 |
| AU2021374976A1 (en) | 2023-06-29 |
| KR20230104223A (ko) | 2023-07-07 |
| CN116406299A (zh) | 2023-07-07 |
| CA3194325A1 (en) | 2022-05-12 |
| CO2023005218A2 (es) | 2023-05-19 |
| JP2023550600A (ja) | 2023-12-04 |
| EP4240335A1 (en) | 2023-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12023500013A1 (en) | Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof | |
| CO2023005218A2 (es) | Nanopartículas lipídicas para administrar vacunas de arnm | |
| MX2022007680A (es) | Nanoparticulas lipidicas para administracion de acidos nucleicos. | |
| MX2024001138A (es) | Arn guia modificados. | |
| MX2024015149A (es) | Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos | |
| GB2596224B (en) | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids | |
| GB2600859B (en) | Improved lipid nanoparticles for delivery of nucleic acids | |
| WO2020051220A8 (en) | Compositions and methods for organ specific delivery of nucleic acids | |
| MX2026002469A (es) | Nuevas moleculas de acido nucleico artificiales | |
| PH12020552100A1 (en) | Modified guide rnas for gene editing | |
| EP4667492A3 (en) | Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes | |
| MX2024002726A (es) | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos. | |
| EP4309739A3 (en) | Core/shell structure platform for immunotherapy | |
| IL317109A (en) | Lipid nanoparticles for the delivery of nucleic acids and methods of using them | |
| MX2024000327A (es) | Composiciones y metodos para la administracion de arn mensajero. | |
| EP4434997A3 (en) | Delivery of negatively charged proteins using cationic lipids | |
| PH12018500965A1 (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| WO2011038160A3 (en) | Compositions and methods for silencing genes expressed in cancer | |
| MX2023009850A (es) | Composiciones y metodos para la administracion de acidos nucleicos. | |
| MX2020011696A (es) | Formulacion arn para inmunoterapia. | |
| EP2574170A4 (en) | IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS | |
| GB2538683A8 (en) | Irinotecan hydrochloride composite phospholipid composition preparation method and use thereof | |
| WO2021247885A3 (en) | Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof | |
| MX2017011298A (es) | Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53. | |
| MX2015000188A (es) | Metodo para producir iduronato-2-sulfatasa recombinante. |